Ferrer to Sell Agendia's Cancer Dx Services | GenomeWeb

Ferrer to Sell Agendia's Cancer Dx Services

Jul 15, 2008

NEW YORK (GenomeWeb News) – Ferrer inCode, the biotech subsidiary of Spanish firm Grupo Ferrer, has gained exclusive rights to sell two of Agendia’s cancer diagnostic services in certain European countries, the firms said today.

Ferrer will offer Agendia’s MammaPrint and CupPrint tests in Germany, France, Italy, and Portugal. Ferrer already sells the tests in Spain under an agreement signed last year.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Breaking News

The Scan

Concerns About Bias in Policies

Researchers representing scientists and students of Chinese descent voice their concerns about recent US policies and rhetoric.

Reprogrammable DNA

Wired reports that researchers have shown they could reprogram a DNA-based computer.

Lack of Diversity

Researchers say increased diversity in genomic studies will benefit all, PBS NewsHour reports.

This Week in Science

In Science this week: whole-genome sequencing of single sperm cells, and more.